Eli Lilly and Company (LLY)
$
985.08
+7.83 (0.79%)
Key metrics
Financial statements
Free cash flow per share
9.9911
Market cap
929.3 Billion
Price to sales ratio
14.2574
Debt to equity
1.6018
Current ratio
1.5791
Income quality
0.8146
Average inventory
13 Billion
ROE
0.9785
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Eli Lilly and Company, established in 1876 and headquartered in Indianapolis, Indiana, discovers, develops, and markets human pharmaceuticals globally. The total costs and expenses for the company are $35,483,000,000.00 reflecting its overall spending on research, development, and various operational activities. The operating income ratio is 0.46 indicating the company's operational profitability margin, showcasing its capacity to manage costs in relation to income generated. Its operational expenses amount to $24,919,000,000.00 encompassing the various costs incurred in pursuing its business objectives. Additionally, the gross profit ratio is 0.84 reflecting the efficiency of the company's production and sales operations amid its diverse product portfolio, which includes treatments for diabetes, various cancers, autoimmune conditions, and mental health disorders. Notable products such as Basaglar, Humalog, Jardiance, Alimta, and Taltz emphasize Lilly's broad impact across multiple therapeutic areas. The diluted EPS is $22.95 accounting for potential share dilution, which is an essential consideration for investors assessing the company's financial health and profitability. In the financial markets, the stock is priced at $751.99 positioning it in the higher-end market and reflecting investor confidence. It has a high average trading volume of 3,079,856.00 indicating strong liquidity that is desirable for both retail and institutional investors. With a large market capitalization of $929,282,113,560.00 the company is a dominant player in the pharmaceutical space, influencing trends and developments within the industry. Eli Lilly is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape through innovative therapies and clinical advancements. Furthermore, it belongs to the Healthcare sector, driving innovation and growth while collaborating with various pharmaceutical and biotechnology firms, which strengthens its position in a competitive environment. The combination of a robust product portfolio and a strategic focus on emerging therapies places Eli Lilly in a favorable position for future success while continuing to meet the evolving needs of patients across the globe.
Is Eli Lilly and Company (LLY) a good investment?
Investing in Eli Lilly and Company (LLY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Eli Lilly and Company (LLY)'s stock forecast?
Analysts predict Eli Lilly and Company stock to fluctuate between $623.78 (low) and $1,133.95 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Eli Lilly and Company's market capitalization?
As of 2026-03-13, Eli Lilly and Company's market cap is $929,282,113,560, based on 943,357,000 outstanding shares.
How does Eli Lilly and Company compare to competitors like Johnson & Johnson?
Compared to Johnson & Johnson, Eli Lilly and Company has a Higher Market-Cap, indicating a difference in performance.
Does Eli Lilly and Company pay dividends?
Eli Lilly and Company pays dividends. The current dividend yield is 0.60%, with a payout of $1.73 per share.
How can I buy Eli Lilly and Company (LLY) stock?
To buy Eli Lilly and Company (LLY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LLY. Place an order (Market, Limit, etc.).
What is the best time to invest in Eli Lilly and Company?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Eli Lilly and Company stock ever split?
Eli Lilly and Company's last stock split was 2:1 on 1997-10-16.
How did Eli Lilly and Company perform in the last earnings report?
Revenue: $65,179,000,000 | EPS: $23 | Growth: 95.58%.
Where can I find Eli Lilly and Company's investor relations reports?
Visit https://www.lilly.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Eli Lilly and Company?
You can explore historical data from here
What is the all-time high and low for Eli Lilly and Company stock?
All-time high: $1,133.95 (2026-01-08) | All-time low: $220.20 (2021-09-28).
What are the key trends affecting Eli Lilly and Company stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
seekingalpha.com
Eli Lilly is rated a strong buy with a $1,623 price target, driven by multiple near- and long-term catalysts. Orforglipron's Q2 launch and Medicare/Medicaid eligibility will expand LLY's addressable market and offset anticipated price erosion. Retatrutide's potential 2027 approval offers another growth leg, with superior efficacy targeting the most severe obesity cases.
reuters.com
India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could act as surrogate promotions, as global and domestic drugmakers seek a share of the country's fast-growing obesity drug market.
reuters.com
Eli Lilly plans to invest $3 billion over the next decade to expand supply chain capacity in China and build production capacity for type-2 diabetes and obesity treatment orforglipron, the pharmaceuticals giant said in a statement.
zacks.com
In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a +1.82% move from the preceding trading day.
fool.com
Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north of $1,200.
reuters.com
Eli Lilly said on Monday a small number of basic Medicare drug plans may not follow the $50 per month cap on out-of-pocket costs for its weight-loss drugs, under the Medicare agency's weight-loss drug coverage model.
zacks.com
Lilly (LLY) reported earnings 30 days ago. What's next for the stock?
cnbc.com
Eli Lilly launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. The "Employer Connect" platform gives employers more flexibility in how they cover obesity treatments, aiming to broaden employee access to the drugs at low out-of-pocket costs, while also keeping costs within budgets.
prnewswire.com
Zepbound® (tirzepatide) KwikPen® for single-patient use available from Lilly at $449 across all doses through the Lilly Employer Connect platform, with reduced cost-share pricing available to employees Flexible benefit designs expand access to obesity treatment while aligning with employer needs and budgets INDIANAPOLIS, March 5, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the launch of its Employer Connect platform, introducing new options to help close the access gap in U.S. obesity care. Lilly's platform expands choice, empowering employers to coordinate with independent program administrators to develop flexible, transparent solutions that enable employee access to obesity management medicines.
See all news
